Mingli Zhong
Nanjing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Prevalence and influencing factors of liver injury in naïve patients with HIV/AIDS in Nanjing from 2005 to 2022: Cross-sectional study.
Journal: Medicine
Published: May 29, 2025
Willingness to Switch to Long-Acting Injectable Cabotegravir and Rilpivirine Every 2 Months for People Living with HIV in Nanjing, China.
Journal: AIDS research and human retroviruses
Published: December 12, 2024
Immunological Efficacy and the Impact on Weight of Dolutegravir-Based Regimen in Antiretroviral Therapy (ART)-Naïve Patients with HIV Infection.
Journal: Infection and drug resistance
Published: August 17, 2024
Pre-existing low-frequency resistance mutations increase the risk of antiretroviral treatment failure in HIV-1 naïve patients.
Journal: Chinese medical journal
Published: July 30, 2023
Prevalence of HIV Transmitted Drug Resistance in Nanjing from 2018 to 2021.
Journal: Infection and drug resistance
Published: September 30, 2022
A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-naïve patients with advanced HIV infection in Nanjing, China.
Journal: Frontiers in immunology
Published: September 06, 2022
Efficacy and Safety of a Simplified Lamivudine Plus Dolutegravir Dual Therapy in HIV-1-Infected Patients: A Multicenter Cohort Study in China.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: December 17, 2021
Ferrite Nanoparticles-Based Reactive Oxygen Species-Mediated Cancer Therapy.
Journal: Frontiers in chemistry
Published: January 08, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026